英文_EFPIA_2025年_制药行业的数字_28页_4mb

EFPIA Key Data Summary

Position in Global Economy

• Europe spent €55,000 million on R&D in 2024, ranking third globally for new drug originators after the US. China surpassed both US and Europe for the first time, with 28 out of 81 new molecules originating from Chinese companies in 2024.
• Despite increased R&D investment, regulatory barriers, rising costs, fiscal austerity, and parallel trade issues have hindered European competitiveness. Parallel trade amounted to €6,497 million in 2023.

Market and Production

• North America (54.8%) dominates the global pharmaceutical market, followed by Europe. China has become a key growth driver, with exports increasing by 14.3% in 2024.
• European production and exports remain strong, but China’s rapid growth challenges traditional market hierarchies.
• In 2024, the combined market value of Europe’s top pharma companies reached approximately €286 billion.

R&D Investment

• Total R&D expenditure in Europe was €52,373 million in 2023, with Germany and Switzerland leading.
• Phase III clinical trial costs average €83 million, and the total cost to bring a new chemical or biological entity to market is estimated at €3.13 billion (Wild & Fabian, 2024).
• R&D intensity varies by country, with Finland having the highest ratio (16%) and EU-wide intensity reaching 18.2% in 2023.

Employment

• The industry directly employs 950,000 people in Europe and indirectly supports three times that number.
• Over 19,000 pharma SMEs contribute significantly to employment across member states.

Market Impact

• Generics account for up to 60% of the pharmaceutical market in some countries, with significant variation across Europe.
• Sales of reimbursed medicines in Europe were €173 billion in 2023 (ambulatory care only).

Parallel Trade

• Approximately 7-8% of pharmaceutical market sales in the EU relate to parallel imports, depriving local industry of revenue and causing supply disruptions.

Other Contributions

• The pharma sector creates high-value jobs in research, academia, and clinical science, helping counteract brain drain.
• Medicines reduce overall healthcare costs by lowering hospital stays and enabling earlier disease treatment.